Skip to main content Accessibility help
×
Home

Left ventricular dysfunction in Duchenne muscular dystrophy

  • Katherine A. James (a1), Jane Gralla (a2), Leslie A. Ridall (a3), ThuyQuynh N. Do (a4), Angela S. Czaja (a3), Peter M. Mourani (a3), Emma Ciafaloni (a5), Christopher Cunniff (a6), Jennifer Donnelly (a3), Joyce Oleszek (a3), Shree Pandya (a5), Elinora Price (a6), Michele L. Yang (a3) and Scott R. Auerbach (a3)...

Abstract

Background:

Duchenne muscular dystrophy is associated with progressive cardiorespiratory failure, including left ventricular dysfunction.

Methods and Results:

Males with probable or definite diagnosis of Duchenne muscular dystrophy, diagnosed between 1 January, 1982 and 31 December, 2011, were identified from the Muscular Dystrophy Surveillance Tracking and Research Network database. Two non-mutually exclusive groups were created: patients with ≥2 echocardiograms and non-invasive positive pressure ventilation-compliant patients with ≥1 recorded ejection fraction. Quantitative left ventricular dysfunction was defined as an ejection fraction <55%. Qualitative dysfunction was defined as mild, moderate, or severe. Progression of quantitative left ventricular dysfunction was modelled as a continuous time-varying outcome. Change in qualitative left ventricle function was assessed by the percentage of patients within each category at each age. Forty-one percent (n = 403) had ≥2 ejection fractions containing 998 qualitative assessments with a mean age at first echo of 10.8 ± 4.6 years, with an average first ejection fraction of 63.1 ± 12.6%. Mean age at first echo with an ejection fraction <55 was 15.2 ± 3.9 years. Thirty-five percent (140/403) were non-invasive positive pressure ventilation-compliant and had ejection fraction information. The estimated rate of decline in ejection fraction from first ejection fraction was 1.6% per year and initiation of non-invasive positive pressure ventilation did not change this rate.

Conclusions:

In our cohort, we observed that left ventricle function in patients with Duchenne muscular dystrophy declined over time, independent of non-invasive positive pressure ventilation use. Future studies are needed to examine the impact of respiratory support on cardiac function.

Copyright

Corresponding author

Author for correspondence: K. A. James, Colorado School of Public Health, University of Colorado, Anschutz Medical Campus, 13001 E 17th PL MS B119 Bldg 500 3rd FLR, Aurora, CO 80045, USA. Tel: 303-724-8169; Fax: 303.724.4620; E-mail: Kathy.James@cuanschutz.edu

References

Hide All
1.Bushby, K, Finkel, R, Birnkrant, DJ, et al.Diagnosis and management of Duchenne muscular dystrophy, part 1: diagnosis, and pharmacological and psychosocial management. Lancet Neurol 2018; 17: 347361.
2.Petrof, BJ, Shrager, JB, Stedman, HH, et al.Dystrophin protects the sarcolemma from stresses developed during muscle contraction. Proc Natl Acad Sci U S A 1993; 90: 37103714.
3.Evans, NP, Miayak, SA, Robertson, JL, et al.Dysregulated intracellular signaling and inflammatory gene expression during initial disease onset in Duchenne muscular dystrophy. Am J Phys Med Rehabil 2009; 88: 502522.
4.Wong, BL, Christopher, C.Corticosteroids in Duchenne muscular dystrophy: a reappraisal. J Child Neurol 2002; 17: 183190.
5.Dubowitz, V.The ‘‘new’’ myopathies. Neuropediatrics 1969; 1: 137148.
6.Tandon, A, Villa, CR, Hor, KN, et al.Myocardial fibrosis burden predicts left ventricular ejection fraction and is associated with age and steroid treatment duration in Duchenne muscular dystrophy. J Am Heart Assoc 2015; 4: e001338.
7.Eagle, M, Baudouin, SV, Chandler, C, et al.Survival in Duchenne muscular dystrophy: improvements in life expectancy since 1967 and the impact of home nocturnal ventilation. Neuromuscular Disorders 2002; 12: 926929.
8.Gomez-Merino, E, Bach, JR. Duchenne muscular dystrophy: prolongation of life by noninvasive ventilation and mechanically assisted coughing. Am J Phys Med Rehabil 2002; 81: 411415.
9.Ishikawa, Y, Miura, T, Ishikawa, Y, et al.Duchenne muscular dystrophy: survival by cardio-respiratory interventions. Neuromusc Disord 2011; 21: 4751.
10.Finsterer, J.Cardiopulmonary support in Duchenne muscular dystrophy. Lung 2006; 184: 205215.
11.Toussaint, M, Soudon, P, Kinnear, W. Effect of non-invasive ventilation on respiratory muscle loading and endurance in patients with Duchenne muscular dystrophy. Thorax 2008; 63: 430434.
12.Hamada, S, Ishikawa, Y, Aoyagi, T, et al.Indicators for ventilator use in Duchenne muscular dystrophy. Respir Med 2011; 105: 625629.
13.Judge, DP, Kass, DA, Thompson, WR, Wagner, KR. Pathophysiology and therapy of cardiac dysfunction in Duchenne muscular dystrophy. Am J Cardiovasc Drugs 2011; 11: 287294.
14.Nigro, G, Comi, LI, Politano, L, Bain, RJI. The incidence and evolution of cardiomyopathy in Duchenne muscular dystrophy. Int J Cardiol 1990; 26: 271277.
15.Fayssoil, A, Nardi, O, Orlikowski, D, Annane, D. Cardiomyopathy in Duchenne muscular dystrophy: pathogenesis and therapeutics. Heart Fail Rev 2010; 15: 103107.
16.Spurney, CF. Cardiomyopathy of Duchenne muscular dystrophy: current understand and future directions. Muscle Nerve 2011; 44: 819.
17.Miller, LA, Romitti, PA, Cunniff, C, et al.The Muscular Dystrophy Surveillance Tracking and Research Network (MD STARnet): surveillance methodology. Birth Defects Res 2006; 76: 793797.
18.Matthews, KD, Cunniff, C, Kantamnent, JR, et al.Muscular Dystrophy Surveillance Tracking and Research Network (MD STARnet): case definition in surveillance for childhood-onset Duchenne/Becker muscular dystrophy. J Child Neurol 2010; 25: 10981102.
19.Connuck, DM, Sleeper, LA, Colan, SD, et al.Characteristics and outcomes of cardiomyopathy in children with Duchenne or Becker muscular dystrophy: a comparative study from the pediatric cardiomyopathy registry. Am Heart J 2008; 155: 9981005.
20.Barber, BJ, Andrews, JG, Lu, Z, et al.Oral corticosteroids and onset of cardiomyopathy in Duchenne muscular dystrophy. J Pediatr 2013; 163: 10801084.
21.Silva, MC, Mahalhaes, TA, Alves Meira, ZM, et al.Myocardial fibrosis progression in Duchenne and Becker muscular dystrophy. JAMA Cardiol 2017; 2: 190199.
22.Gudmundsson, P, Rydberg, E, Winter, R, Willenheimer, R. Visually estimated left ventricular ejection fraction by echocardiography is closely correlated with formal quantitative methods. Int J Cardiol 2005; 101: 209212.
23.Birnkrant, DJ, Ashwath, ML, Noritz, GH, et al.Cardiac and pulmonary function variability in Duchenne/Becker muscular dystrophy: an initial report. J Child Neurol 2010; 25: 11101115.
24.Roberto, R, Fritz, A, Hagar, Y, et al.The natural history of cardiac and pulmonary function decline in patients with Duchenne muscular dystrophy. Spine 2011; 36: E1009E1017.
25.Humbertclaude, V, Hamroun, D, Bezzou, K, et al.Motor and respiratory heterogeneity in Duchenne patients: implication for clinical trials. Eur J Pediatr Neurol 2012; 16: 149160.
26.Romfh, A, McNally, EM. Cardiac assessment in Duchenne and Becker muscular dystrophies. Curr Heart Fail Rep 2010; 7: 212218.
27.Romitti, PA, Zhu, Y, Puzhankara, S, et al.; on behalf of the MD STARnet. Prevalence of Duchenne and Becker muscular dystrophies in the United States. Pediatrics 2015; 135: 513521. doi:10.1542/peds.2014-2044.
28.Duiverman, ML, Wempe, JB, Bladder, G, et al.Two-year home-based nocturnal noninvasive ventilation added to rehabilitation in chronic obstructive pulmonary disease patients: a randomized controlled trial. Resp Res 2011; 12: 112119.
29.Tandon, A, Jefferies, JL, Villa, CR, et al.Dystrophin genotype-cardiac phenotype correlations in Duchenne and Becker muscular dystrophies using cardiac magnetic resonance imaging. Am J Cardiol 2015; 115: 967971.
30.Fitzmaurice, GM, Ravidchandran, C. A primer in longitudinal data analysis. Circulation 2008; 118: 20052010.
31.Schram, G, Fournier, A, Leduc, H, et al. All-cause mortality and cardiovascular outcomes with prophylactic steroid therapy in Duchenne muscular dystrophy. JACC 2013; 61: 948954.
32.Duboc, D, Meune, C, Pierre, B, et al.Perindopril preventive treatment on mortality in Duchenne muscular dystrophy: 10 years’ follow-up. Am Heart J 2007; 154: 596602.
33.Birnkrant, DJ, Bushby, K, Bann, CM, et al.Working Group. Diagnosis and management of Duchenne muscular dystrophy, part 1: diagnosis, and neuromuscular, rehabilitation, endocrine, and gastrointestinal and nutritional management. Lancet Neurol 2018; 17: 251267.
34.McNally, EM, Kaltman, JR, Benson, DW, et al.Contemporary cardiac issues in Duchenne muscular dystrophy. Working Group of the National Heart, Lung, and Blood Institute in collaboration with Parent Project Muscular Dystrophy. Circulation 2015; 131: 15901598.
35.Wittlieb-Weber, CA, Pantea, C, Krikov, S, et al.Cardiovascular health supervision for Duchenne Muscular Dystrophy; data from the MD STARnet. Progr Pediatr Cardiol 2018; 48: 98104.

Keywords

Related content

Powered by UNSILO

Left ventricular dysfunction in Duchenne muscular dystrophy

  • Katherine A. James (a1), Jane Gralla (a2), Leslie A. Ridall (a3), ThuyQuynh N. Do (a4), Angela S. Czaja (a3), Peter M. Mourani (a3), Emma Ciafaloni (a5), Christopher Cunniff (a6), Jennifer Donnelly (a3), Joyce Oleszek (a3), Shree Pandya (a5), Elinora Price (a6), Michele L. Yang (a3) and Scott R. Auerbach (a3)...

Metrics

Full text views

Total number of HTML views: 0
Total number of PDF views: 0 *
Loading metrics...

Abstract views

Total abstract views: 0 *
Loading metrics...

* Views captured on Cambridge Core between <date>. This data will be updated every 24 hours.

Usage data cannot currently be displayed.